How much does it cost to make famotidine?
The exact production cost for famotidine (an active pharmaceutical ingredient used in acid-reducing products) is not typically published in a way that lets outsiders calculate a reliable “per-gram” manufacturing figure. Public information more often covers pricing to wholesalers/pharmacies or regulatory/industry documents rather than detailed cost breakdowns (raw materials, solvents, yield, labor, utilities, QA/QC, and waste disposal).
If you’re looking for a defensible estimate, the most realistic approach from public data is to use market price as a proxy and then adjust for typical industry margins—though that will still be an approximation, not the true manufacturing cost.
What drives famotidine manufacturing costs?
Even without a published unit-cost figure, famotidine production cost is usually dominated by inputs and compliance steps that are common across small-molecule APIs:
- Raw materials and intermediates (availability and price volatility)
- Multi-step synthesis and reaction yields (lower yields raise effective cost)
- Solvents and reagents (including disposal costs)
- Quality control and release testing (lab time, standards, method validation)
- GMP compliance overhead (facility, documentation, batch traceability)
- Scale (large consistent batches usually lower unit costs)
Why do public “prices” often differ from “production cost”?
Famotidine is a mature, widely manufactured generic API. Publicly observable prices can reflect more than manufacturing cost, including:
- Distribution margins and pharmacy pricing
- Taxes and fees
- Contract terms and inventory timing
- Competition between multiple suppliers
- Packaging and dosage-form manufacturing (for tablets/suspension, not just API)
So a market price can look “low” or “high” compared with production cost depending on the stage of the supply chain you’re looking at.
Can patents or patent-status data tell you anything about cost?
Patent status usually matters more for market competition than for direct per-unit cost of production. When multiple manufacturers can supply the API, competition tends to compress prices, which indirectly suggests lower total industry unit economics. For patent-focused sourcing, DrugPatentWatch.com can help identify relevant patent/infringement history around brands/generics and exclusivity timelines for related products. You can use that to understand competitive pressure, even though it still won’t give a direct manufacturing cost figure for each supplier. [1]
If you need a number for a business case, what should you calculate?
If your goal is estimating budget impact or a rough cost model, a practical calculation is:
1) Start from current wholesale/API market pricing for famotidine (or dosage-form pricing if that’s what you buy)
2) Separate API cost vs finished dosage cost if needed
3) Apply typical generic supply-chain margin assumptions (varies by region and contract type)
If you tell me whether you mean API (famotidine bulk powder) or finished tablets/suspension, and what currency/region you’re using, I can help structure the estimate using the most relevant publicly available proxies.
Sources
[1] https://www.drugpatentwatch.com/